Back HIV/AIDS

HIV / AIDS

IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study

Bristol-Myers Squibb's HIV attachment inhibitor BMS-663068 (fostemsavir), which prevents the virus from binding to T-cells, demonstrated good antiviral activity and was well-tolerated at 24 weeks, according to study results published recently in Lancet HIV. Findings from a subgroup analysis at 48 weeks, presented at IDWeek 2015 this week in San Diego, showed that response rates were similar regardless of demographics or baseline viral load or CD4 cell count.

alt

ICAAC 2015: No Transmission of Integrase Inhibitor-Resistant HIV Seen in California Patients

Not one case of transmission of HIV that is resistant to any of the integrase inhibitor drugs has been seen among newly diagnosed patients in a database of resistance tests in California, according to a presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)last month in San Diego.

alt

IDWeek 2015 Features HIV and Hepatitis C Prevention, Treatment, and Cure Research

Immediate antiretroviral therapy is the big HIV news of the year and interferon-free therapy has transformed the treatment of hepatitis C despite its high cost, experts said during an overview of "What's Hot" in the field, presented at the IDWeek 2015 conference taking place this week in San Diego. Participants also heard a keynote talk by Ian Crozier, a doctor who survived Ebola virus disease.

alt

IDWeek 2015: Affordable Care Act Coverage Improves Chances of HIV Viral Suppression

Enrolling low-income and under-insured people with HIV in an Affordable Care Act (ACA) health plan improves their odds of having sustained antiretroviral treatment and undetectable viral load, according to a presentation at ID Week 2015 in San Diego. This study adds to the recent evidence confirming the benefits of providing healthcare coverage for people living with HIV.

alt

Recent Infection and Treatment Interruptions Are Key Periods for HIV Transmission

A large proportion of HIV transmissions occur during recent infection or antiretroviral therapy interruptions, Swiss investigators report in the September 19 advance edition of Clinical Infectious Diseases. Overall, 44% of transmissions were associated with recent infection and 14% could be attributed to treatment interruptions. The authors believe these findings represent a major challenge for treatment as prevention (TasP) strategies.

alt

Certain Vaginal Bacteria May Protect Against HIV Transmission During Sex

Specific types of Lactobacillus bacteria in the vaginal mucus can trap HIV and may help prevent sexual transmission of the virus to women, according to a report in the October 6 edition of the online journal mBio. Conversely, researchers found that another species associated with bacterial vaginosis may increase susceptibility to HIV infection.

alt

People with HIV Are at Higher Risk for Several Types of Cancer, Large Study Finds

People living with HIV remain at risk for AIDS-defining cancers in the era of effective antiretroviral therapy, and also have higher rates of several non-AIDS cancers than the general population, including lung, anal, and liver cancer, according to findings from a study of more than 86,000 HIV-positive people published in the October 6 Annals of Internal Medicine.

alt